ProQR Therapeutics N.V.
corporate_fare Company Profile
ProQR Therapeutics N.V. (NASDAQ:PRQR) is a publicly traded company in the Life Sciences sector. Wiseek monitors PRQR SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Major Shareholder Threatens Legal Action After Opposing 61% Dilution at AGM
- Shareholders Approve Capital Increase and Board's Authority to Issue Shares
- ProQR Therapeutics Q1 Revenue Plummets, Missing Estimates by Over 60%
- ProQR Reports Wider Q1 Loss and Significant Revenue Miss; Pipeline Advances with Extended Cash Runway
- ProQR Reports Q1 2026 Results, Advances RNA Editing Pipeline, and Refines Lead Program Strategy
Financial Snapshot
Insider Transactions
PRQR files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.